X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Ensuring global vaccine equity requires eliminating trade and regulatory barriers

By Megan Van Etten  |    August 5, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.   Read More

Increasing global access to vaccines by optimizing production

By Megan Van Etten  |    July 29, 2021
The following is part of a series of posts detailing each of the five strategies to advance global COVID-19 vaccine equity – which rely on and benefit from a strong intellectual property ecosystem.   Read More

Dose sharing as a part of the COVID-19 global vaccine equity strategy

By Megan Van Etten  |    July 20, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.   Read More

Promoting global vaccine equity while protecting innovation

By Megan Van Etten  |    July 15, 2021
America’s biopharmaceutical companies have successfully researched, developed and distributed billions of doses of multiple vaccines and therapeutics to halt the spread of COVID-19. The...   Read More

New polling shows Americans are sounding the alarm on the TRIPS IP waiver

By Cynthia Hicks  |    May 14, 2021
Last week, the Biden administration announced support for a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which could lead...   Read More

The Biden Administration allows politics to upend a pragmatic pandemic response

By Megan Van Etten  |    May 14, 2021
Last week, the Biden Administration announced that it will support a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which...   Read More

New report demonstrates development of new medicines relies on private sector expertise and investment

By John Corea  |    May 10, 2021
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. Critical to this...   Read More

American leadership on innovation policy is essential to global health progress

By Ernest Kawka  |    May 4, 2021
Over the last year, the world has witnessed the importance of strong innovation policies as intellectual property protection and market access policies facilitated the research, development and...   Read More

Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections

By Megan Van Etten  |    April 9, 2021
Earlier this week PhRMA submitted comments to the National Institute of Standards and Technology (NIST) regarding the proposed rulemaking on implementing regulations of the Bayh-Dole Act. Passed...   Read More

Intellectual property is the key to vaccine development, manufacturing and technology sharing

By Megan Van Etten  |    March 5, 2021
Earlier today, 31 PhRMA board members signed a letter to President Joe Biden applauding the Administration’s accelerating COVID-19 vaccine rollout, but also warning against efforts to undermine...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates